MartinEduardoGutierrezMD

Oncology • Hackensack, NJ

Director Drug Discovery/Phase I Research Chief of Thoracic Oncology Member of GI Division

Join to view full profile

Dr. Gutierrez is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Gutierrez's full profile

Already have an account?

Office
92 2nd St
Hackensack, NJ 07601
Phone+1 551-996-5863

Fax+1 551-996-0580

Summary

As co-chief, Thoracic Oncology, and director of the Phase 1 Program, I specialize in bringing Phase 1 clinical trials to cancer patients treated at John Theurer Cancer Center. The approximately 40 Phase 1 trials currently in place are focused on immunotherapy, targeted therapies, and cell technologies such as CAR-T therapy, which engineers T-cells to target cancer.

Martin Gutierrez, M.D., treats patients with lung and gastrointestinal cancers

Dr. Martin Gutierrez, co-chief, Thoracic Oncology and director, Phase 1 Program at John Theurer Cancer Center, treats patients with lung and gastrointestina...

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1997 - 2000
Boston University Medical CenterResidency, Internal Medicine, 1993 - 1996
Pontifical Xavierian UniversityClass of 1991

Certifications & Licensure

DC State Medical License 2024 - 2027
NY State Medical License 2021 - 2026
NJ State Medical License 2011 - 2025
FL State Medical License 2000 - 2014
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014

Clinical Trials

Study of Neoadjuvant CT With Selective Radiotherapy in Patients With Intermediate-Risk Cancer Rectum Start of enrollment: 2009 Mar 01
Completed
Phase 2
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies Start of enrollment: 2014 Feb 01
Completed
Phase 1
A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer Start of enrollment: 2018 Mar 07
Recruiting
Phase 2
Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer Start of enrollment: 2012 Nov 23
Completed
Phase 2
Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients Start of enrollment: 2013 Apr 01
Completed
Phase 1
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma Start of enrollment: 2013 Mar 01
Completed
Phase 1
Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib Start of enrollment: 2013 Aug 01
Completed
Phase 2
Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers Start of enrollment: 2013 Apr 01
Terminated
Phase 1, Phase 2
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors Start of enrollment: 2013 Nov 01
Completed
Phase 1
Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
No longer available
Testing Spectrosense EVA System for Detection of Pancreatic Cancer by Analyzing Volatile Organic Compounds (VOCs) in Exhaled Air Start of enrollment: 2013 Oct 01
Unknown status
Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors Start of enrollment: 2014 Feb 01
Completed
Phase 1
Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment Start of enrollment: 2014 Apr 01
Completed
Phase 1
LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel Start of enrollment: 2014 Jul 01
Withdrawn
Phase 1
A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors Start of enrollment: 2017 Feb 23
Terminated
Phase 1
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors Start of enrollment: 2018 Oct 01
Completed
Phase 1, Phase 2
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies Start of enrollment: 2019 May 17
Recruiting
Phase 1
A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas Start of enrollment: 2019 Sep 18
Recruiting
Phase 1, Phase 2
A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations Start of enrollment: 2022 Apr 18
Active, not recruiting
Phase 1
Roles: Contact
A Study of SGN-EGFRd2 in Advanced Solid Tumors Start of enrollment: 2023 Nov 14
Recruiting
Phase 1
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Phase II Parallel Arm Study of Sacituzumab Govitecan-Hziy in Patients With Advanced Thymoma or Thymic Carcinoma.
Jennifer A Marks, Jaeil Ahn, Joshua E Reuss, David Barbie, Mehmet Altan
Clinical Lung Cancer. 2024-12-04
2 citations
T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study.
Justin F Gainor, Manish R Patel, Jeffrey S Weber, Martin Gutierrez, Julie E Bauman
Cancer Discovery. 2024-11-01
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors.
Maxime Chénard-Poirier, Aaron R Hansen, Martin E Gutierrez, Drew Rasco, Yan Xing
Investigational New Drugs. 2024-06-01

Lectures

Utilization of next generation sequencing (NGS) and rates of undergenotyping in patients with metastatic colon cancer (mCC) treated at academic and community centers i...
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/25/2020
Rates of genotyping for , , , microsatellite instability (MSI), and mismatch repair (MMR) in metastatic colon cancer patients: Gaps and implications.
ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
Real-world characterization of advanced/metastatic non-small cell lung cancer (aNSCLC) patients (pts) with rapid disease progression (RDP).
ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
Biomarker-directed precision oncology of pembrolizumab-based combination therapy for non-small cell lung cancer: Phase II KEYNOTE-495/KeyImPaCT study.
ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019
Join now to see all

Press Mentions

Bristol Myers Squibb Research at ESMO Congress 2022 Highlights Depth of Development Program Across Early- and Late-Stages of CancerSeptember 5th, 2022
Molecular Tumor Testing Transformative, yet 'Under-Optimized'July 23rd, 2021
NextCure to Present Trials in Progress Poster for NC410 at the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingMay 19th, 2021
Join now to see all